Oncotype DX Breast DCIS Score^® test

The Oncotype DX Breast DCIS Score test is for patients who:

• Have been recently diagnosed with DCIS and are making treatment decisions with their doctor
• Have had a lumpectomy or biopsy

It’s performed after the original surgery to remove your DCIS tumor, but before you start treatment—because the test is intended to help guide treatment decisions. Learn more about how the breast DCIS Score test works.

Genetic tests help people understand their risk for getting cancer. Genomic tests help people who have been diagnosed with cancer with their treatment planning. Once you have cancer, the activity of certain genes in your tumor tissue influences the behavior of your tumor, including how likely it is to grow and spread. The Oncotype DX Breast DCIS Score test looks at these genes to help you and your doctor make decisions about your care.

There are five different anatomic stages of breast cancer: 0, I, II, III, and IV. These stages tell you how much the cancer has grown and spread. For example, stage 0 cancer is an early form of cancer that is not invasive and contained in one place, while stage IV is cancer that has spread throughout the body. Learn more about the anatomic stages of cancer.

If you have ductal carcinoma in situ (DCIS), you have stage 0 (non-invasive) cancer. “In situ” means that the cancer cells have not spread outside the milk duct. Only patients with DCIS are eligible for the Breast DCIS Score test.

If you have anatomic stage I, II, or IIIA breast cancer, you may be eligible for the Oncotype DX Breast Recurrence Score^® test.

Estrogen and progesterone are 2 of the hormones in your body. They have many roles, including facilitating the reproductive process. In (and on) breast cells, there are “hormone receptors”—proteins that pick up hormone signals. If the cancer cells in your breast have hormone receptors, they are called "HR-positive." HR-positive cancer cells (like normal breast cells) may receive signals from estrogen—so the cancer might respond to hormonal therapy. If the cancer cells don’t have hormone receptors, they are classified as "HR-negative." With HR-negative cancer cells, hormonal treatment is unlikely to work, so your doctor will look for other options.

Patients with either HR-positive or HR-negative DCIS may qualify for the Oncotype DX breast DCIS Score test .

Most results from the Breast DCIS Score test are available around 2 weeks from the date the tumor sample is received by the Exact Sciences lab.^* The results are sent to your doctor so that they can discuss the results with you and answer your questions.

The Oncotype DX Breast DCIS Score test is covered by Medicare, and private insurance coverage varies. In addition, Exact Sciences Genomic Access Program (GAP) helps patients navigate insurance and other payment options for Oncotype DX tests. Learn more about insurance coverage and financial assistance.